Imbruvica ibrutinib: Phase II data

Data from 60 treatment-naive patients with follicular lymphoma in the open-label, U.S. Phase II PCYC-1125-CA trial showed that once-daily 560 mg oral Imbruvica plus 4 doses of once-weekly 375 mg/m 2 IV Rituxan rituximab led to an ORR of 82%, including a 27% complete response rate and a 55% partial response rate, at a median follow-up of 10.2 months. Median time to best response was 2.7 months. Median PFS, OS and duration of response have not yet been reached. Next month, data will be presented at the American Society of Hematology meeting in Orlando. ...